Insider trade

Cytokinetics (CYTK): EVP Research & Development sold ~$177K

Fady Ibraham Malik, EVP Research & Development at Cytokinetics, sold ~$177K of Cytokinetics shares.

~$177K
Approx. value · 2,907 sh @ $60.72
139K
Holds after · shares reported
Traded
Mar 9, 2026
Filed
Mar 10, 2026

What stands out in this filing

  • The sale was 2.1% of the shares this insider held before it; the filing reports 138,629 shares afterwards.
  • 2,907 shares at an average of $60.72 each, as reported on the form.
  • Footnote references tax withholding.

Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Feb 2, 2026InsiderOfficer sold ~$55K of CYTK shares in the open market
  2. Feb 5, 2026InsiderOfficer sold ~$929K of CYTK shares in the open market
  3. Feb 24, 2026Company filing · Form 8-K · ResultsReported its results
  4. Mar 2, 2026Insider · 2 peopleInsiders: 2 sales (~$361K)
  5. Mar 5, 2026Insider · 1 personInsiders: 2 sales (~$1.6M)
  6. Mar 9, 2026 · this disclosureInsiderOfficer sold ~$177K of CYTK shares in the open market

What came next

  1. Mar 9, 2026Insider · 2 peopleInsiders: 2 sales (~$638K)
  2. Mar 16, 2026InsiderOfficer sold ~$104K of CYTK shares in the open market
  3. Mar 17, 2026Insider · 4 peopleInsiders: 7 sales (~$3.9M)
  4. Mar 18, 2026InsiderOfficer sold ~$120K of CYTK shares in the open market
  5. Mar 31, 2026InsiderOfficer sold ~$237K of CYTK shares in the open market
  6. Apr 1, 2026InsiderCEO sold ~$500K of CYTK shares in the open market
  7. Apr 7, 2026Insider · 1 personInsiders: 2 sales (~$293K)
  8. Apr 15, 2026Insider · 2 peopleInsiders: 2 sales (~$982K)
  9. Apr 21, 2026InsiderOfficer sold ~$230K of CYTK shares in the open market
  10. Apr 29, 2026InsiderCEO sold ~$447K of CYTK shares in the open market
  11. Apr 30, 2026InsiderOfficer sold ~$949K of CYTK shares in the open market
  12. May 1, 2026InsiderOfficer sold ~$1.03M of CYTK shares in the open market
  13. May 5, 2026Company filing · Form 8-K · ResultsReported its results
  14. May 5, 2026Insider · 5 peopleInsiders: 5 sales (~$4.8M)
  15. May 14, 2026InsiderCEO sold ~$584K of CYTK shares in the open market
  16. May 19, 2026InsiderOfficer sold ~$265K of CYTK shares in the open market
  17. May 27, 2026InsiderCEO sold ~$579K of CYTK shares in the open market
  18. Jun 1, 2026Insider · 3 peopleInsiders: 3 sales (~$1.7M)
  19. Jun 9, 2026InsiderOfficer sold ~$238K of CYTK shares in the open market
  20. Jun 15, 2026InsiderCEO sold ~$528K of CYTK shares in the open market
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Cytokinetics

For Cytokinetics, OQRO holds 26 insider filings (SEC Form 4 or Form 144) and 1 Congress trade report dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its CYTK page.

Other recent filings by Fady Ibraham Malik, EVP Research & Development

The full history of Fady Ibraham Malik, EVP Research & Development is on the profile page.

How this filing works

Explore the data

Common questions

Which Cytokinetics (CYTK) insider traded, and how much?

Fady Ibraham Malik, EVP Research & Development at Cytokinetics, sold ~$177K of Cytokinetics shares. 2,907 shares at $60.72.

When did it happen, and when was it made public?

Traded: Mar 9, 2026. Filed: Mar 10, 2026. That is 1 day between the two dates.

What stands out in this filing?

The sale was 2.1% of the shares this insider held before it; the filing reports 138,629 shares afterwards. 2,907 shares at an average of $60.72 each, as reported on the form. Footnote references tax withholding.

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Cytokinetics recently?

For Cytokinetics, OQRO holds 26 insider filings (SEC Form 4 or Form 144) and 1 Congress trade report dated in the last 90 days. They are listed on the CYTK page.

Does this mean CYTK stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Cytokinetics

Everything OQRO holds on this company is on its CYTK page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data